General Information of This Drug (ID: DMNFNK7)

Drug Name
Zunsemetinib   DMNFNK7
Synonyms
zunsemetinib; ATI-450; (R)-Zunsemetinib; Zunsemetinib [INN]; ATI450; CDD450; Zunsemetinib [USAN]; CDD-450; AX2VWG0ZCR; 1640282-42-3; 1639791-42-6; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; UNII-AX2VWG0ZCR; Zunsemetinib M-atropisomer; Zunsemetinib [USAN:INN]; Ati 450; ATI 450 [WHO-DD]; CHEMBL3704901; SCHEMBL16279876; GTPL11681; BDBM175242; EX-A6292; WHO 11983; AKOS040756965; HY-139553A; MS-29543; HY-139553; CS-0204147; CS-0374185; US9115089, 49; (-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one
Drug Type
Small molecule
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cryopyrin-associated periodic syndrome DISPXXOZ 4A60.1 Phase 2 [1]
Hidradenitis suppurativa DIS3ZNAK ED92.0 Phase 2 [2]
Rheumatoid arthritis DISTSB4J FA20 Phase 2 [3]
Psoriatic arthritis DISLWTG2 FA21 Phase 2 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04524858) A Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of ATI-450 for the Maintenance of Remission in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed With Anti-IL-1 Therapy. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05216224) A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe HS. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT04247815) A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT05511519) A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis. U.S.National Institutes of Health.